Table 3

Univariate and multivariate prognostic analyses for MFS

CharacteristicsUnivariateMultivariate
NHR (95% CI)P valueNHR (95% CI)P value*
Age (years)3711.00 (0.99 to 1.01)0.902
Gender
 Male vs female3711.02 (0.70 to 1.49)0.909
Tumor site
 Head and neck vs extremity3820.00 (0.00 to Inf)0.66
 Internal trunk vs extremity0.77 (0.50 to 1.18)
 Superficial trunk vs extremity0.81 (0.47 to 1.40)
Depth
 Superficial vs deep1960.78 (0.38 to 1.61)0.495
Pathological type
 Liposarcoma vs leiomyosarcoma6780.48 (0.35 to 0.67)1.35E−066780.58 (0.41 to 0.81)1.51E−03
 Myxofibrosarcoma vs leiomyosarcoma0.45 (0.24 to 0.86)6780.52 (0.27 to 0.98)4.44E−02
 Other vs leiomyosarcoma0.21 (0.08 to 0.57)6780.25 (0.09 to 0.69)7.65E−03
 Undifferentiated sarcoma vs leiomyosarcoma0.43 (0.30 to 0.61)6780.47 (0.33 to 0.68)4.40E−05
Pathological tumor size, cm2101.00 (0.96 to 1.04)0.898
Pathological FNCLCC grade
 3 vs 1–23071.43 (0.95 to 2.17)0.088
CINSARC risk
 High vs low6782.48 (1.87 to 3.28)2.03E−106782.19 [1.65 to 2.92)8.14E−08
ICR classification
 1 vs 2–36781.59 (1.20 to 2.08)1.11E−036781.52 (1.15 to 2.00)3.54E−03
  • *Wald test.

  • FNCLCC, Fédération Nationale des Centres de Lutte Contre le Cancer; ICR, immunologic constant of rejection; MFS, metastasis-free survival .